Hugh H. Varner, Ph.D., received his doctorate in Biochemistry from the Medical University of South Carolina, and pursued a career in basic research as a postdoctoral and staff fellow at the National Institutes of Health, and as a faculty member at Baylor College of Medicine in Houston. He moved into commercial bioscience as a researcher with Baltimore Biotech, Inc., which was eventually acquired by Celtrix. While there, he was involved in drug design and evaluation, including synthesis, characterization and preclinical efficacy studies. In 1989, Dr. Varner joined Chesapeake Biological Laboratories, Inc., a contract manufacturer of clinical trial through commercial presentations of parenteral drugs. He is currently Director, Tech Transfer Group, and is responsible for evaluation of potential new products and design of processes for their integration into the manufacturing capabilities of the company.